AbbVie Inc (ABBV, Financial)(30-Year Financial) files its latest 10-K with SEC for the fiscal year ended on December 31, 2019. AbbVie Inc is a biopharmaceutical company that discovers, develops, manufactures and sells a range of pharmaceutical products for treating chronic autoimmune diseases, virology and neurological disorders. AbbVie Inc has a market cap of $139.59 billion; its shares were traded at around $94.39 with a P/E ratio of 17.87 and P/S ratio of 4.28. The dividend yield of AbbVie Inc stocks is 4.66%. AbbVie Inc had annual average EBITDA growth of 14.70% over the past five years. GuruFocus has detected 1 severe warning sign with AbbVie Inc. .
For the last quarter AbbVie Inc reported a revenue of $8.7 billion, compared with the revenue of $8.3 billion during the same period a year ago. For the latest fiscal year the company reported a revenue of $33.3 billion, an increase of 1.6% from last year. For the complete 30-year financial data, please go here.. For the last five years AbbVie Inc had an average revenue growth rate of 11.2% a year.
The reported diluted earnings per share was $5.28 for the year, an increase of 44.3% from previous year. Over the last five years AbbVie Inc had an EPS growth rate of 26.5% a year. The AbbVie Inc enjoyed an operating margin of 40.19%, compared with the operating margin of 20.78% a year before. The 10-year historical median operating margin of AbbVie Inc is 32.70%. The profitability rank of the company is 9 (out of 10).
At the current stock price of $94.39, AbbVie Inc is traded at close to its historical median P/S valuation band of $93.00. The P/S ratio of the stock is 4.28, while the historical median P/S ratio is 4.21. The stock gained 23.29% during the past 12 months.
For the complete 20-year historical financial data of ABBV, click here.
